Cargando…
Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model
The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular sp...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447521/ https://www.ncbi.nlm.nih.gov/pubmed/32705145 http://dx.doi.org/10.1093/brain/awaa179 |
_version_ | 1783574318838448128 |
---|---|
author | Harrison, Ian F Ismail, Ozama Machhada, Asif Colgan, Niall Ohene, Yolanda Nahavandi, Payam Ahmed, Zeshan Fisher, Alice Meftah, Soraya Murray, Tracey K Ottersen, Ole P Nagelhus, Erlend A O’Neill, Michael J Wells, Jack A Lythgoe, Mark F |
author_facet | Harrison, Ian F Ismail, Ozama Machhada, Asif Colgan, Niall Ohene, Yolanda Nahavandi, Payam Ahmed, Zeshan Fisher, Alice Meftah, Soraya Murray, Tracey K Ottersen, Ole P Nagelhus, Erlend A O’Neill, Michael J Wells, Jack A Lythgoe, Mark F |
author_sort | Harrison, Ian F |
collection | PubMed |
description | The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer’s disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer’s disease, and possibly other neurodegenerative diseases alike. |
format | Online Article Text |
id | pubmed-7447521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-74475212020-08-27 Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model Harrison, Ian F Ismail, Ozama Machhada, Asif Colgan, Niall Ohene, Yolanda Nahavandi, Payam Ahmed, Zeshan Fisher, Alice Meftah, Soraya Murray, Tracey K Ottersen, Ole P Nagelhus, Erlend A O’Neill, Michael J Wells, Jack A Lythgoe, Mark F Brain Original Articles The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer’s disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer’s disease, and possibly other neurodegenerative diseases alike. Oxford University Press 2020-08 2020-07-23 /pmc/articles/PMC7447521/ /pubmed/32705145 http://dx.doi.org/10.1093/brain/awaa179 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Harrison, Ian F Ismail, Ozama Machhada, Asif Colgan, Niall Ohene, Yolanda Nahavandi, Payam Ahmed, Zeshan Fisher, Alice Meftah, Soraya Murray, Tracey K Ottersen, Ole P Nagelhus, Erlend A O’Neill, Michael J Wells, Jack A Lythgoe, Mark F Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model |
title | Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model |
title_full | Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model |
title_fullStr | Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model |
title_full_unstemmed | Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model |
title_short | Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model |
title_sort | impaired glymphatic function and clearance of tau in an alzheimer’s disease model |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447521/ https://www.ncbi.nlm.nih.gov/pubmed/32705145 http://dx.doi.org/10.1093/brain/awaa179 |
work_keys_str_mv | AT harrisonianf impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT ismailozama impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT machhadaasif impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT colganniall impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT oheneyolanda impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT nahavandipayam impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT ahmedzeshan impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT fisheralice impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT meftahsoraya impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT murraytraceyk impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT ottersenolep impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT nagelhuserlenda impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT oneillmichaelj impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT wellsjacka impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel AT lythgoemarkf impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel |